



an Open Access Journal by MDPI

Inflammatory Bowel Diseases: New Diagnostic and Therapeutic Approaches

Guest Editors:

Dr. Maria Manuela Estevinho

1. Department of Gastroenterology, Vila Nova de Gaia Espinho Hospital Center, Vila Nova de Gaia, Portugal

2. Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal

Dr. Fernando Magro

1. Department of Gastroenterology, São João Hospital University Centre, Porto, Portugal

2. Unidade de Farmacologia Clínica, São João Hospital University Centre, Porto, Portugal

3. Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal

Message from the Guest Editors

Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are lifelong gastrointestinal tract disorders whose prevalence is projected to reach 1% by 2030. It is now evident that IBDs arise from a complex interplay of genetic, environmental, and microbial factors, leading to dysregulated immune responses. However, there are still several unresolved aspects that limit timely diagnosis and therapeutic options, impacting patients' prognosis and quality of life. Therefore, it is crucial to encourage research that addresses the existing knowledge gaps. In this Special Issue, we invite original research or review articles focused on various topics related to IBD, including: Mechanisms underlying IBD pathogenesis; Disease monitoring; Biomarkers; Pharmacological innovations (new targets and combination therapy); Endoscopic treatment; Risk stratification and individualized therapy; Management of extraintestinal manifestations; Comorbidities in patients with IBD

Deadline for manuscript submissions:

closed (31 August 2024)



mdpi.com/si/175476

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI